VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth?
These two healthcare ETFs offer investors exposure to some of medicine's biggest names, but their different approaches to investing could lead to very different results.
When weighing investment options within the healthcare sector, investors face a choice between the VanEck Biotech ETF and the Invesco S&P 500 Equal Weight Health Care ETF. The biotech-focused VanEck fund targets a narrow slice of genetic research and drug manufacturing, with only 25 holdings. By contrast, the Invesco fund takes a broader approach, spreading investments across 61 major healthcare companies within the S&P 500, with a 98% allocation to the healthcare sector.
Investors can expect a slightly lower expense ratio for the VanEck fund at 0.35%, compared to 0.40% for the Invesco fund. However, the Invesco fund provides a higher dividend yield, offering 0.6% versus 0.4% for the biotech-focused alternative. The Invesco fund also spreads risk across more companies, with its largest holdings including Moderna, Illumina, and Mettler-Toledo International, among others.
For long-term investors, the Invesco S&P 500 Equal Weight Health Care ETF appears to present a more appealing opportunity. With its broader diversification and higher dividend yield, the fund spreads risk more effectively across the healthcare industry. While the VanEck Biotech ETF offers the appeal of substantial growth potential in the rapidly evolving biotechnology sector, the broader exposure and lower risk of the Invesco fund make it the better choice for investors seeking long-term growth in healthcare without over-relying on a small group of biotech companies.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
